These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21151038)

  • 21. Refining the treatment parameters of diabetic retinopathy: new prospects and limitations on the horizon.
    Ziemssen F; Spital G
    J Diabetes Complications; 2014; 28(2):119. PubMed ID: 24360342
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparative effectiveness of anti-VEGF agents for diabetic macular edema.
    Ollendorf DA; Colby JA; Pearson SD
    Int J Technol Assess Health Care; 2013 Oct; 29(4):392-401. PubMed ID: 24290332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravitreal anti-vascular endothelial growth factor therapy with bevacizumab for tuberous sclerosis with macular oedema.
    Saito W; Kase S; Ohgami K; Mori S; Ohno S
    Acta Ophthalmol; 2010 May; 88(3):377-80. PubMed ID: 18778334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.
    Kumar V; Ghosh B; Raina UK; Goel N
    Acta Ophthalmol; 2010 Mar; 88(2):e3; author reply e4. PubMed ID: 19549100
    [No Abstract]   [Full Text] [Related]  

  • 25. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for anti-VEGF treatment of diabetic macular edema.
    Bandello F; Berchicci L; La Spina C; Battaglia Parodi M; Iacono P
    Ophthalmic Res; 2012; 48 Suppl 1():16-20. PubMed ID: 22907145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antivascular endothelial growth factor as an approach for macular edema.
    Buchholz PM; Buchholz AP; Augustin AJ
    Dev Ophthalmol; 2010; 46():111-122. PubMed ID: 20703037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on nonsurgical therapy for diabetic macular edema.
    Witkin AJ; Brown GC
    Curr Opin Ophthalmol; 2011 May; 22(3):185-9. PubMed ID: 21427573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The article by Kook et al 1 on the 1-year effect of bevacizumab in patients with chronic diffuse diabetic macular edema (DME).
    Querques G
    Retina; 2009 May; 29(5):718-9; author reply 719-20. PubMed ID: 19430285
    [No Abstract]   [Full Text] [Related]  

  • 30. Diabetic retinopathy: intravitreal vascular endothelial growth factor inhibitors for diabetic macular oedema.
    Mohamed QA; Fletcher EC; Buckle M
    BMJ Clin Evid; 2016 Mar; 2016():. PubMed ID: 27031563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary.
    Giuliari GP; Guel DA; Cortez MA; Cortez RT
    Can J Ophthalmol; 2010 Oct; 45(5):501-8. PubMed ID: 20648074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of diabetic retinopathy with anti-VEGF drugs.
    Waisbourd M; Goldstein M; Loewenstein A
    Acta Ophthalmol; 2011 May; 89(3):203-7. PubMed ID: 21044274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paracentesis before intravitreal injection of bevacizumab.
    Tsui YP; Chiang CC; Tsai YY
    Can J Ophthalmol; 2008 Apr; 43(2):239; author reply 239-40. PubMed ID: 18347632
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparison of a single intravitreal injection of bevacizumab versus triamcinolone acetonide as primary treatment for diffuse diabetic macular oedema.
    Penha FM; Maia M; Cardillo JA; Arevalo JF; Wu L; Rodriguez FJ; Berrocal MH; Farah ME;
    Acta Ophthalmol; 2012 Mar; 90(2):e160-1. PubMed ID: 21470386
    [No Abstract]   [Full Text] [Related]  

  • 35. Anti-VEGF therapy in proliferative diabetic retinopathy.
    Abdallah W; Fawzi AA
    Int Ophthalmol Clin; 2009; 49(2):95-107. PubMed ID: 19349790
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
    Shimura M; Nakazawa T; Yasuda K; Shiono T; Iida T; Sakamoto T; Nishida K
    Am J Ophthalmol; 2008 May; 145(5):854-61. PubMed ID: 18328456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
    Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
    Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes of aqueous vascular endothelial growth factor and pigment epithelium-derived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion.
    Park SP; Ahn JK
    Clin Exp Ophthalmol; 2009 Jul; 37(5):490-5. PubMed ID: 19624346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
    Chong V
    Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin).
    Nagpal M; Nagpal K; Nagpal PN
    Indian J Ophthalmol; 2007; 55(6):437-9. PubMed ID: 17951900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.